lodoxamide-tromethamine and Keratoconjunctivitis

Superior limbic keratoconjunctivitis (SLK) is a chronic and recalcitrant disease of the superior bulbar and tarsal conjunctiva, as well as the superior limbic aspect of the cornea. Both the etiology and the pathogenesis of this condition are poorly understood. Many treatment options have been advocated in the management of SLK, including: topical antibiotics, topical anti-inflammatory agents, topical vitamin A solutions, chemical cautery, thermal cautery, and surgical resection. Most recently, studies have suggested that lacrimal occlusion therapy may be beneficial in the treatment of SLK. A case is presented in which this method of treatment was used, with excellent results. The implications of this report suggest that the use of lacrimal occlusion in the management of SLK may be a viable treatment option before considering more radical and invasive therapy. In addition, this case helps to illustrate the significant link between SLK and thyroid disease.

Topics: Adult; Female; Humans; Keratoconjunctivitis; Lacrimal Apparatus; Nitriles; Oxamic Acid; Prostheses and Implants; Silicones; Thyroid Hormones; Treatment Outcome; Tromethamine

We studied the efficacy of topically applied lodoxamide tromethamine 0.1% in the treatment of superior limbic keratoconjunctivitis.. Three patients with clinical findings of bilateral superior limbic keratoconjunctivitis. were treated with topical lodoxamide tromethamine four times daily in both eyes.. While the patients were taking lodoxamide tromethamine, symptoms and objective findings resolved.. Topically applied lodoxamide tromethamine 0.1% is useful in the treatment of superior limbic keratoconjunctivitis. There may be a role for mast cell stabilizers in the treatment of this disorder.

Topics: Administration, Topical; Adult; Conjunctiva; Female; Histamine H1 Antagonists; Humans; Keratoconjunctivitis; Male; Middle Aged; Nitriles; Ophthalmic Solutions; Oxamic Acid; Tromethamine